Floatz logo

Sat-3247

Muscular Dystrophies

Satellos Bioscience, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Muscular Dystrophies cohort.

Asset / SponsorPhaseRating
gsk2402968
GlaxoSmithKline
Phase 3BB
Ataluren
PTC Therapeutics
Phase 3B
Tadalafil
University of Florida
Phase 2B
Zeleciment Rostudirsen
Dyne Therapeutics
Phase 3B
Enalapril
InCor Heart Institute
Phase 3B

View all 11 →

Same molecule, other indications

Sat-3247 is also rated in:

Duchenne muscular dystrophyDormant
B
Indicative ·
58 / 100
View asset →
neuromuscular diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →